What is PT-141 (Bremelanotide)?
PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide derived as the active metabolite of Melanotan 2 (MT-2). Unlike MT-2's broad non-selective activity across melanocortin receptors, PT-141 has evolved in its research profile toward a more selective focus on MC4R and MC3R — the CNS-expressed receptor subtypes linked to arousal and appetite — while its MC1R activity (and therefore its melanogenic effect) is substantially reduced. This narrower receptor profile makes PT-141 a distinct research tool from its parent compound, studied primarily for its central, non-vascular influence on sexual arousal in preclinical models.
What PT-141 Is
PT-141 is a cyclic heptapeptide — seven amino acids in a ring structure — that emerged from the Melanotan 2 research program. It is formally a metabolite of MT-2: when MT-2 is exposed to enzymatic degradation in biological systems, one of its breakdown products is this structurally related compound that retains CNS melanocortin receptor activity but loses most of its peripheral MC1R/melanogenic action.
The name "Bremelanotide" reflects its pharmaceutical research designation. The "PT" prefix in "PT-141" refers to its origins as a peptide tanning compound, though modern research has largely shifted away from the pigmentation applications toward the central nervous system receptor pharmacology it enables.
Mechanism of Action
PT-141 acts as a Gs-coupled GPCR agonist at the melanocortin receptor family, with its activity concentrated at two CNS-expressed subtypes:
MC4R — the primary research target: MC4R is broadly expressed throughout the central nervous system — hypothalamus, limbic system, brainstem, and cortex. Activation of MC4R by PT-141 triggers Gs→adenylyl cyclase→cAMP→PKA signaling in these neurons. Research into MC4R in the context of sexual arousal has focused on its role in the mesolimbic dopamine system, hypothalamic oxytocin release, and the modulation of pro-erectile/pro-receptive neural circuits — pathways that are independent of peripheral vascular tone.
MC3R — modulatory role: MC3R is co-expressed in hypothalamic regions alongside MC4R. Its activation is thought to modulate the feedback tone of the central melanocortin system. In sexual arousal research, MC3R's contribution is studied as ancillary to the dominant MC4R pathway.
Reduced MC1R activity: Unlike MT-2, PT-141 shows substantially reduced affinity at MC1R — the peripheral receptor on skin melanocytes responsible for melanogenesis. This means PT-141 does not significantly upregulate eumelanin production, removing a major confounding variable when the research goal is to isolate CNS melanocortin effects.
Central vs Peripheral: PT-141 vs PDE5 Inhibitors
The mechanistic distinction between PT-141 and phosphodiesterase type 5 (PDE5) inhibitors is one of the most frequently cited aspects of PT-141 research literature:
| Parameter | PT-141 (Bremelanotide) | PDE5 Inhibitors (e.g. Sildenafil) |
|---|---|---|
| Site of action | Central nervous system (hypothalamus, limbic) | Peripheral vascular smooth muscle |
| Receptor target | MC4R / MC3R (melanocortin GPCRs) | PDE5 enzyme (cGMP pathway) |
| Mechanism | Gs→cAMP→PKA (neural activation) | Inhibits cGMP breakdown → NO-driven vasodilation |
| Nitric oxide dependency | No — mechanism is independent | Yes — requires endogenous NO signaling |
| Applicability in female models | Studied in both sexes (central mechanism) | Primarily male-focused (vascular anatomy) |
| Research use case | CNS melanocortin pathway modulation | Peripheral vascular / erectile function |
The two mechanistic pathways are not mutually exclusive in research — some studies examine the combined or additive effects of central melanocortin activation alongside peripheral vascular support. But for researchers specifically trying to characterize the neural component of arousal in isolation, PT-141's non-vascular, central mechanism is a key differentiator.
Male and Female Research Models
One of the more notable features of PT-141 research is its application in both male and female preclinical models — a contrast to the historical focus of PDE5 inhibitor research on male vascular physiology.
Because MC4R and MC3R are expressed throughout the CNS regardless of sex, and because PT-141's mechanism does not depend on sex-specific peripheral anatomy, it has been studied for effects on sexual arousal and desire endpoints in female models including measures of solicitation behavior, genital engorgement in non-vascular-dependent models, and subjective arousal analog measures in higher-order animal models.
This makes PT-141 a reference compound for researchers studying the neurological — rather than vascular — dimension of sexual function and for comparative work between arousal pathways in different sexes.
PT-141 vs MT-2 (Melanotan 2)
PT-141 and MT-2 are closely related — PT-141 is a metabolite of MT-2 — but their receptor profiles diverge in a way that matters for research design:
| Parameter | MT-2 (Melanotan 2) | PT-141 (Bremelanotide) |
|---|---|---|
| MC1R activity | Strong agonist → melanogenesis | Substantially reduced → minimal pigmentation effect |
| MC3R activity | Agonist | Agonist |
| MC4R activity | Agonist | Agonist (primary research focus) |
| Selectivity profile | Non-selective (MC1/3/4R) | CNS-selective (MC3/4R dominant) |
| Primary research use | Melanogenesis, full melanocortin spectrum | CNS arousal pathways, MC4R pharmacology |
| Light sensitivity | High — requires light protection | Moderate — standard peptide storage precautions |
Researchers choose MT-2 when the goal involves the full melanocortin receptor picture (including MC1R/melanogenesis), and choose PT-141 when the goal is to isolate the CNS melanocortin pathway without the peripheral pigmentation variable. See our What is MT-2 guide for a full breakdown of the parent compound.
Reconstitution for Research
PT-141 is supplied as a lyophilized (freeze-dried) powder and must be reconstituted with Bacteriostatic Water before use in research protocols.
Standard protocol for the 10mg vial: Add 2 mL Bacteriostatic Water for a concentration of 5 mg/mL. Inject the BAC Water slowly down the vial wall and swirl gently — do not shake. The solution should be clear and colorless. Unlike MT-2, PT-141 does not require special light protection beyond standard peptide handling precautions. Refrigerate at 2–8°C after reconstitution. Stable 28–42 days.
For full reconstitution parameters and a dosing calculator that computes exact draw volumes, visit our Reconstitution Guide and Dosing Calculator.